Guggenheim downgrades Apple, drops $245 price target

Photo of Steven M. Peters
By Steven M. Peters Updated Published

Analyst Robert Cihra has lost faith in “growth via ASPs,” won’t hazard a guess on where the stock is headed.

 

From a note to clients that landed on my desktop Wednesday morning:

Key Message: Whereas a year ago AAPL looked like a table-pounder when iPhone units were weak but about to be more than offset by a big jump in ASPs (+17%Y/Y in FY18), which ultimately drove Apple’s best iPhone revenue growth in 3 years, we rather now find that setup flipped with “growth via ASPs” widely known but just as those ASPs start to anniversary. Over the past 10 years, Apple’s iPhone ASP has increased a dramatic + $220, or 40%, reflecting its growing value to both consumer and business markets, but nearly HALF of all that just came in FY18 alone, making a period of digestion now likely…

With the iPhone screen an incredibly valuable piece of real estate, we continue to forecast Apple growing its Services revs +19%Y/Y in FY19E… But while that model continues to grow and helps support the stock’s P/E, we still consider Apple a “product” company. Ever since Apple launched its iPhone Upgrade Program 3 years ago, we have thought it could eventually migrate to selling its entire product+services portfolio as some sort of “subscription” to loyal users who upgrade anyway (e.g., $1K/year to be part of the Apple ecosystem, with a fresh iPhone, iPad, Mac, etc.), but have not seen it move that way.

Downgrades rating to Neutral from Buy. Removes $245 price target.

Cue Cihra’s revenue growth bar chart:

guggengeim downgrades

My take: He still considers Apple a “product company.”

[apple-subscribe]

Contact [email protected] for any questions or corrections.

Photo of Steven M. Peters
About the Author Steven M. Peters →

Our $500K AI Portfolio

See us invest in our favorite AI stock ideas for free

Our Investment Portfolio

Continue Reading

Top Gaining Stocks

ABNB Vol: 15,913,532
MCHP Vol: 19,139,274
PLTR Vol: 77,244,625
MRNA Vol: 6,820,582
AXON Vol: 1,591,869

Top Losing Stocks

TTD Vol: 133,458,224
CTRA Vol: 73,319,495
AKAM Vol: 8,143,961
ZTS Vol: 12,784,553
RMD Vol: 3,810,438